Vimarsana
Biggest News Aggregation in the World

Et Cest News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Et Cest. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Et Cest Today - Breaking & Trending Today

u-blox AG: u-blox reports first nine months 2023 revenue of CHF 436 million - Vimarsana News

u-blox AG: u-blox reports first nine months 2023 revenue of CHF 436 million

U-blox AG / Key word(s): 9 Month figures u-blox AG: u-blox reports first nine months 2023 revenue of CHF 436 million 11-Oct-2023 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Ad hoc announcement pu...

EQS-News: Wienerberger AG: wienerberger presents innovative solutions at Capital Markets Day 2023 in Belgium - Vimarsana News

EQS-News: Wienerberger AG: wienerberger presents innovative solutions at Capital Markets Day 2023 in Belgium

EQS-News: Wienerberger AG / Key word(s): Conference/Sustainability Wienerberger AG: wienerberger presents innovative solutions at Capital Markets Day 2023 in Belgium 11.10.2023 / 14:00 CET/CEST The issuer is solely responsible for the content of this announcement. wienerberger presents innovativ...

EQS-News: PlusPlus announces terms of Buyback offer for EUR 2022/2026 Bonds - Vimarsana News

EQS-News: PlusPlus announces terms of Buyback offer for EUR 2022/2026 Bonds

EQS-News: PlusPlus Capital Financial S.à.r.l. / Key word(s): Bond PlusPlus announces terms of Buyback offer for EUR 2022/2026 Bonds 11.10.2023 / 14:30 CET/CEST The issuer is solely responsible for the content of this announcement. PlusPlus announces terms of Buyback offer for EUR 2022/2026 Bonds...

EQS-News: Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at MSMilan2023: The 9th Joint ECTRIMS-ACTRIMS Meeting - Vimarsana News

EQS-News: Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at MSMilan2023: The 9th Joint ECTRIMS-ACTRIMS Meeting

Issuer: Immunic, Inc. / Key word(s): Study results/Conference Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at MSMilan2023: The 9th Joint ECTRIMS-ACTRIMS Meeting 11.10.2023 / 12:30 CET/CEST The issuer is solely responsible for...

u-blox AG: u-blox introduces new functionally safe end-to-end positioning solution for autonomous driving - Vimarsana News

u-blox AG: u-blox introduces new functionally safe end-to-end positioning solution for autonomous driving

U-blox AG / Key word(s): Product Launch u-blox AG: u-blox introduces new functionally safe end-to-end positioning solution for autonomous driving 10.10.2023 / 09:00 CET/CEST u-blox introduces new functionally safe end-to-end positioning solution for autonomous driving u-blox u-safe is a pre-cert...